The US FDA approved 1 NDAs and 2 BLA in October 2022, leading to treatments for patients and advances in the healthcare industry. The CDER and CBER approved 66 novel products in 2022
In October 2022, the major highlights drugs were Tecvayli’s approval for relapsed or refractory multiple myeloma, Furoscix for congestion in chronic heart…
INTRODUCTION
Also known as seizure disorder, epilepsy is a non-communicable chronic disorder of the brain and is the fourth most common neurological disease globally. It is a central nervous system (CNS) disorder characterized by recurrent episodes of seizures that are short changes in normal brain activity which led to brief incidences of involuntary movements either…
Shots:
Emily spoke about the launch of the new visual identity of Merz Aesthetics. The identity is built on the idea to create a cohesive and clear visual identity for Merz Aesthetics that reflects who they are and the purpose to fuel confidence
The brightness of this new identity includes shades of orange, yellow, green,…
Shots:
Dr. Susan talked about the results from the SOLO-1 P-III trial of Lynparza in patients with BRCA mutated (BRCAm) newly diagnosed advanced ovarian cancer presented at ESMO’22
Dr. Susan also spoke about the overall survival of this 7-year follow-up study.The 7-year follow-up of SOLO-1 showed that olaparib provided a clinically meaningful improvement in OS…
Shots:
Bill spoke about Respiratory Syncytial Virus and how it can severely affect infants' health
Bill also talked about the 14 studies on RSV published in the Journal of Infectious Diseases (JID)
The interview gives an understanding of how Sanofi’s vision to develop innovative solutions to help reduce the burden of RSV on infants, families,…
It has been quite evident that the trends in the number of clinical trials associated with neurological conditions have experienced many alterations over the past 8 years (2015-2022). Through our analysis, we came across, that the number of studies increased at a moderate rate between 2015-2019 until it suffered a significant dip in 2020 due…
Shots:
Simon spoke about the new data on FETROJA (cefiderocol), an antibiotic for the treatment of serious Gram-negative (highly resistant) bacterial infections
He also talked about Shionogi’s agreement with GARDP & CHAI for the manufacturing and commercialization of cefiderocol in different countries
The interview summarizes how Shionogi is advancing by developing medicines to treat serious…
Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potency
Biosimilars are expected to be a cost-effective alternative to the high-priced branded biologics, offering significant and much-needed cost savings to both payers and the patients
During the month of October, Similis Bio entered into a development and…
Shots:
Martin gave a detailed view of the newly launched Honey Analytics module associated with the Trialbee Honeyâ„¢ platform
He also talked about the how Trialbee Honey platform will help in the screening and recruiting of patients specifically in remote areas
The interview gives a profound understanding of how Trialbee is developing real-time monitoring modules…
Shots:
Natalie spoke about the study design and key findings from the P-III study evaluating Stelara for the treatment of pediatric patients with active psoriatic arthritis
She also spoke about the patient support program that is executed by Janssen to support patients to get StelaraÂ
The interview gives an understanding of how Janssen is advancing…

